 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...481482483484485486487488489490491...508509» |
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 5, 2015
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2015 --> Oct 2016
- Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche
Trial primary completion date: Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas (clinicaltrials.gov) - Feb 5, 2015
P2, N=52, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Sep 2015 --> Sep 2016
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Feb 5, 2015
P1/2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
- carboplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open, Surgery, Metastases: Short-course HIPEC in Advanced Epithelial Ovarian Cancer (clinicaltrials.gov) - Feb 5, 2015
P2, N=20, Enrolling by invitation, Sponsor: Professor Fernando Figueira Integral Medicine Institute
Trial primary completion date: Sep 2015 --> Sep 2016 Not yet recruiting --> Enrolling by invitation
- prednisolone / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes (clinicaltrials.gov) - Feb 5, 2015
P2, N=50, Completed, Sponsor: Cancer Institute WIA
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Sep 2013
- |||| Trial completion, Trial primary completion date, Surgery: AREN0321: Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors (clinicaltrials.gov) - Feb 5, 2015
P2, N=294, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Sep 2013 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2014
- Beleodaq (belinostat) / Aurobindo, Assertio
Trial primary completion date, Combination therapy, Metastases: A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies (clinicaltrials.gov) - Jan 30, 2015
P1/2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2014 Trial primary completion date: Jun 2015 --> Dec 2015
- Lartruvo (olaratumab) / Eli Lilly
Enrollment open, Metastases: A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 30, 2015
P1, N=24, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jun 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- |||||| Rituxan (rituximab) / Roche
Enrollment open: Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jan 30, 2015
P3, N=560, Recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: LAL1308: Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 30, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Nov 2014
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion, Enrollment change, Metastases: The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP (clinicaltrials.gov) - Jan 30, 2015
P2, N=15, Completed, Sponsor: Mahidol University
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Nov 2014 Active, not recruiting --> Completed | N=30 --> 15
- | mitomycin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: HIPEC/IPHC: Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (clinicaltrials.gov) - Jan 29, 2015
P2, N=200, Recruiting, Sponsor: Bay Area Gynecology Oncology
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date: Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=30, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed | N=30 --> 15 Trial primary completion date: May 2015 --> May 2016
- |||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial primary completion date: TITAN: A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 28, 2015
P3, N=614, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Jan 2015 --> Sep 2016
- ||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Trial initiation date, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - Jan 28, 2015
P1, N=248, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2015 --> Sep 2016 Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014
- ||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a (clinicaltrials.gov) - Jan 28, 2015
P3, N=746, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- ||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed, Combination therapy: A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jan 28, 2015
P3, N=576, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Trial completion, Metastases: LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - Jan 28, 2015
P2, N=150, Completed, Sponsor: British Columbia Cancer Agency
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
P3 data: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Jan 26, 2015
P3, N=600, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Initiation date: Dec 2014 --> Apr 2015
- ||||||| thalidomide / Generic mfg.
Trial completion, Post-transplantation: UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy (clinicaltrials.gov) - Jan 26, 2015
P3, N=673, Completed, Sponsor: University of Arkansas
Initiation date: Dec 2014 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2014 | Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Clinical: Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=10, Recruiting, Sponsor: InSightec
- | Onureg (azacitidine oral) / BMS
New P1 trial: A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma (clinicaltrials.gov) - Jan 22, 2015
P1, N=50, Not yet recruiting, Sponsor: Celgene Corporation
- Pixuvri (pixantrone) / Servier, Rituxan (rituximab) / Roche
Enrollment change: A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (clinicaltrials.gov) - Jan 20, 2015
P2, N=124, Completed, Sponsor: CTI BioPharma
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2014 | Active, not recruiting --> Completed N=280 --> 124
- Enrollment open: Vaccination of High Risk Breast Cancer Patients (clinicaltrials.gov) - Jan 18, 2015
P1/2, N=61, Recruiting, Sponsor: University of Arkansas
N=280 --> 124 Not yet recruiting --> Recruiting
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 18, 2015
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, PARP Biomarker, Metastases: Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 15, 2015
P1, N=90, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Jun 2015
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment change, Combination therapy: Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients (clinicaltrials.gov) - Jan 15, 2015
P1/2, N=32, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Dec 2014 --> Jun 2015 N=10 --> 32
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Gene therapy: Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=5, Not yet recruiting, Sponsor: City of Hope Medical Center
- Trial completion, Enrollment change, Trial primary completion date: Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer (clinicaltrials.gov) - Jan 15, 2015
P2, N=72, Completed, Sponsor: City of Hope Medical Center
N=10 --> 32 Active, not recruiting --> Completed | N=100 --> 72 | Trial primary completion date: Nov 2014 --> Dec 2013
- || Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial initiation date, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - Jan 13, 2015
P1, N=248, Not yet recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=100 --> 72 | Trial primary completion date: Nov 2014 --> Dec 2013 Initiation date: Jun 2014 --> Mar 2014
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Phase classification, Trial primary completion date: CEAL: Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 13, 2015
P2, N=68, Recruiting, Sponsor: University of Magdeburg
Initiation date: Jun 2014 --> Mar 2014 Phase classification: P3 --> P2 | Trial primary completion date: Oct 2010 --> Dec 2015
- |||||| Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) (clinicaltrials.gov) - Jan 13, 2015
P3, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P3 --> P2 | Trial primary completion date: Oct 2010 --> Dec 2015 Active, not recruiting --> Recruiting
- | Campath (alemtuzumab) / Sanofi
Enrollment closed, Trial primary completion date, Combination therapy, IO biomarker: ACT-1: Alemtuzumab and CHOP in T-cell Lymphoma (clinicaltrials.gov) - Jan 9, 2015
P3, N=308, Active, not recruiting, Sponsor: Aarhus University Hospital
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
- ||| cytarabine / Generic mfg.
Clinical: CARMEN: Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=1200, Enrolling by invitation, Sponsor: Registro de Fibrilación Auricular y Riesgo Embólico en México
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date, Post-transplantation: PTLD-1/3: Risk Stratified Sequential Treatment for CD20-positive PTLD (clinicaltrials.gov) - Jan 8, 2015
P2, N=150, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Dec 2014
- cyclophosphamide / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open: TRIUMPH: TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen (clinicaltrials.gov) - Jan 6, 2015
P2, N=45, Recruiting, Sponsor: Jules Bordet Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open, Post-transplantation: PTLD-2: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (clinicaltrials.gov) - Jan 6, 2015
P2, N=90, Recruiting, Sponsor: Diako Ev. Diakonie-Krankenhaus gemeinn
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
Enrollment closed, Metastases: Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer (clinicaltrials.gov) - Jan 6, 2015
P2, N=126, Active, not recruiting, Sponsor: NSABP Foundation Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2018
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Metastases: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (clinicaltrials.gov) - Jan 2, 2015
P1, N=31, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Dec 2015 --> Dec 2018 N=53 --> 31
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
N=53 --> 31 Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion: A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma (clinicaltrials.gov) - Jan 2, 2015
P1, N=33, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (clinicaltrials.gov) - Dec 31, 2014
P1, N=31, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open, Enrollment change: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a (clinicaltrials.gov) - Dec 30, 2014
P3, N=900, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=746 --> 900
- Enrollment change: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma (clinicaltrials.gov) - Dec 29, 2014
P2, N=80, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Recruiting | N=746 --> 900 N=64 --> 80
- | Lartruvo (olaratumab) / Eli Lilly
New P1 trial, Metastases: A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 29, 2014
P1, N=24, Not yet recruiting, Sponsor: Eli Lilly and Company
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial primary completion date: Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov) - Dec 25, 2014
P2, N=60, Active, not recruiting, Sponsor: City of Hope Medical Center
N=64 --> 80 Trial primary completion date: Mar 2014 --> Mar 2016
- ||||| Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) (clinicaltrials.gov) - Dec 25, 2014
P3, N=161, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2014 --> Mar 2016 Recruiting --> Active, not recruiting
- ||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed, Trial primary completion date: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a (clinicaltrials.gov) - Dec 25, 2014
P3, N=746, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Mar 2017
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: IELSG30: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (clinicaltrials.gov) - Dec 24, 2014
P2, N=35, Recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Mar 2017 Trial primary completion date: Dec 2013 --> Mar 2015